Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Aart Beeker has a total of 273 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Clinician-Reported Respiratory Viral Testing and Intended Management of Community-Acquired Respiratory Viral Infections in Haematology and Haematopoietic Cell Transplantation: An International Exploratory Survey

    by Justin R. du Toit, Tobias R. Neijzen, Sjoerd van der Bie, Steven F. L. van Lelyveld, Aart Beeker, Karlijn J. van Stralen, Odette M. Vlek, Estelle R. Verburgh, Eric van Gorp, Jurjen Versluis, et al.

    Background: Community-acquired respiratory viruses (CARVs) cause significant morbidity and mortality in patients with haematological malignancies and those undergoing haematopoietic cell transplantation (HCT). Despite this, clinical management remains variable. This study evaluated clinicians’ awareness, diagnostic practices, and treatment approaches to major respiratory viruses in this high-risk population. Methods: An international electronic survey using non-probability convenience sampling was conducted among haematology, oncology, intensive care and emergency medicine physicians. Four real-life clinical cases were converted into standardised vignettes covering human metapneumovirus (HMPV), respiratory syncytial virus (RSV), human parainfluenza virus (HPIV) and influenza A virus (IAV). The questionnaire assessed reported testing strategies and intended management, including antiviral and immunoprophylactic interventions. Responses were analysed descriptively; no inferential between-group comparisons were performed. Results: Ninety-eight clinicians from 26 countries responded. Diagnostic approaches, including testing indications and panel selection, varied among respondents. For HMPV and HPIV, respondents mainly reported supportive care, immunoglobulin replacement, and infection-control measures in the absence of established pathogen-specific interventions. RSV practice was heterogeneous: systemic ribavirin was considered by 45/96 (46.9%) respondents, including 34/96 (35.4%) when guided by an immunodeficiency score. IAV management was more consistent, with reported availability of vaccination and antiviral therapy and frequent use of post-exposure prophylaxis. Conclusions: Within this international convenience sample, clinicians reported variation in respiratory viral testing and in how results informed intended management. Because sampling was non-probability-based and respondent groups were small and unevenly distributed, the findings should not be interpreted as representative estimates of international practice. IAV testing was most consistently linked to established treatment and prevention, RSV showed greater therapeutic and preventive heterogeneity, and HMPV/HPIV testing primarily informed infection control, monitoring and antimicrobial stewardship.

  • Open Access

    Hypomethylating agents with venetoclax for newly diagnosed acute myeloid leukemia in patients 65 and older in The Netherlands – A nationwide study of drug usage and treatment outcomes

    by Benno Diekmann, Carolien M. Woolthuis, Maarten F. Corsten, David de Leeuw, Roel B. Fiets, Elena Segarceanu, Fleur M. van der Valk, Tim T. de Waal, Marjan Cruijsen, Eva de Jongh, et al.


  • Open Access

    Effects of exercise and diet in patients with incurable gastroesophageal cancer: the RADICES study

    by Aniek Bonhof, Anouk E Hiensch, Nicolette J Wierdsma, Linde F Huis In ‘t Veld, Sandra D Bakker, Aart Beeker, Marjan Davidis-Van Schoonhoven, Helga Droogendijk, Jan C Drooger, Joeri A J Douma, et al.

    Background: Patients with incurable gastroesophageal adenocarcinoma have an impaired health-related quality of life (HRQOL). Exercise combined with nutritional support may improve this outcome. Careful evaluation of this supportive care strategy is needed to avoid burdening patients at this vulnerable stage with interventions that may offer no (meaningful) benefit. Therefore, this study aims to investigate the effects of a combined exercise and nutritional intervention on HRQOL in patients with incurable gastroesophageal adenocarcinoma. Methods: RADICES (the effect of exeRcise And Diet on quality of life in patients with Incurable Cancer of Esophagus and Stomach) is a multicenter randomized controlled trial aiming to include 196 patients with incurable gastroesophageal adenocarcinoma. Participants are randomly assigned (1:1) to a patient-tailored intervention or a control group. The intervention group is provided with 2 training sessions per week and biweekly nutritional consultations, delivered by trained physiotherapists and dietitians, during 12 weeks. The control group receives usual care supplemented with general physical activity advice. The primary outcome is the difference in HRQOL between the intervention group and the control group at 12 weeks, accounting for baseline HRQOL, measured by the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire–30 summary score. HRQOL is assessed at baseline, 6 weeks, 12 weeks, and every 3 months thereafter up to 1 year. Key secondary outcomes include patient-reported outcomes, cardiorespiratory fitness, dietary intake, disease progression, overall survival, and cost-effectiveness. Adherence and safety are monitored throughout the intervention period. Conclusion: This study will generate evidence on the effectiveness of a patient-tailored combined exercise and nutritional intervention in patients with incurable gastroesophageal adenocarcinoma. If effective for HRQOL, this intervention could be integrated into standard care for patients with incurable gastroesophageal adenocarcinoma. Trial registration: clinicaltrials.gov NCT06138223. Date of trial registration: November 18, 2023 Date and version study protocol: 28-04-2025 version 3.1 Date start recruitment: 19-01-2024


  • Top Cited Papers
    Open Access

    Drawing cancer chronicles: A qualitative study to evaluate narrative meaning-making over time and in response to a meaning-centred care intervention

    by Emily R.E. Evans, Niels van Poecke, Maite Portela, Michael Scherer-Rath, Yvonne Weeseman, Zarah M. Bood, Nirav Christophe, Henny Dörr, Judith de Vos-Geelen, Aart Beeker, et al.

    The diagnosis of incurable cancer can disrupt life stories, undermining meaning-making and challenging self-identity. People may therefore need to search for and create new stories about their lives that incorporate their diagnosis. Arts-based narrative interventions are being explored to support this existential process of narrative meaning-making. However, developing effective existential support may be limited by the lack of methods capable of investigating their impact. This study is the first to explore narrative meaning-making across time and a meaning-centred care intervention by longitudinally using ‘Rich Pictures’ (RPs) – hand-drawn visual narratives. We analysed repeated RPs about living with incurable cancer from thirty-eight participants in two studies: one incorporating an arts-based narrative intervention, and one without. RPs were compared across time and the two groups using an inductive, multi-level, and participatory analysis approach. Our findings highlighted six strategies variably used by participants to reconstruct their narratives over time: repeating, retaining, repurposing, reinforcing, reducing, and reassembling. Differences were found in the employment of these strategies between the two different studies, with arts-based intervention participants predominantly developing new ways of narrating and relating to cancer as a disruptive life event. We conclude that people living with incurable cancer employ a range of strategies in reconstructing their narratives. Arts-based interventions may support this existential process. The repeated use of RPs is a valuable method for investigating narrative meaning-making over time, across groups, and interventions, offering insights to evaluate and develop meaning-centred care in oncology.


  • Health-related quality of life with first- vs second-line CDK4/6 inhibitor use in advanced breast cancer: results from the SONIA trial

    by Noor Wortelboer, Seamus Kent, Hedwig M Blommestein, Annemiek van Ommen-Nijhof, Vincent van der Noort, Esther van Den Pol, Cristina Guerrero Páez, Aart Beeker, Karin Beelen, Lisanne C Hamming, et al.

    Background: The SONIA trial demonstrated that addition of cyclin-dependent kinase 4 and 6 inhibitors (CDK4/6i) to first-line endocrine therapy (aromatase-inhibitor) was not superior in terms of progression-free survival after 2 treatment lines compared with addition to second-line (fulvestrant), while first-line use increased toxicity (74% more grade ≥3 adverse events) and costs. Understanding the impact of both treatment strategies on health-related quality of life (HRQOL) is critical to inform patient-centered treatment decisions. Methods: HRQOL was assessed using the Functional Assessment of Cancer Therapy-Breast (FACT-B) and EuroQoL 5-dimensions 5-level questionnaires at up to 11 time points over the course of both treatment lines (follow-up) until SONIA treatment discontinuation. FACT-B total and subscale scores—including physical, social, emotional, functional well-being, and the breast cancer subscale—along with EuroQoL 5-dimensions 5-level scores were compared between treatment strategies using mixed linear regression models. Clinically meaningful differences were predefined as 7 points for the FACT-B total score and 2 points for subscales. Results: Questionnaire completion rates for FACT-B were 88% at baseline and 75% during follow-up. No clinically or statistically significant differences in HRQOL were observed between treatment arms during follow-up. The estimated mean difference in FACT-B total score (CDK4/6i in second-line as reference) was −0.66 (95% confidence interval [CI] = −2.14 to 0.82; P = .39). Differences for subscales were similarly small. Conclusion: HRQOL was comparable between patients receiving CDK4/6i in first- vs second-line across all measures, despite differences in toxicity rates. Clinical Trial Registration: ClinicalTrials.gov (NCT03425838; https://www.clinicaltrials.gov/study/nct03425838).


  • Open Access

    Atezolizumab consolidation in patients with high-risk diffuse large B-cell lymphoma in complete remission after R-CHOP

    by Marcel Nijland, Djamila E. Issa, Johanna A. A. Bult, Dries Deeren, Gerjo A. Velders, Marten R. Nijziel, Yorick Sandberg, Vibeke Vergote, Margriet Oosterveld, Rob Fijnheer, et al.

    The risk of relapse among high-risk patients with diffuse large B-cell lymphoma (DLBCL) in complete metabolic remission (CMR) after rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisolone (R-CHOP) therapy is 20% to 25%. Here, we evaluated whether consolidation with the programmed cell death ligand 1 checkpoint inhibitor atezolizumab could reduce the relapse risk. In this phase 2, open-label trial, patients with DLBCL with an International Prognostic Index (IPI) score of ≥3 and CMR after R-CHOP received 1200 mg atezolizumab every 3 weeks for 18 cycles. The primary end point was disease-free survival (DFS) at 2 years, with the aim of improving it to 89% compared to historical 79%. Secondary end points included overall survival (OS) and safety (Common Terminology Criteria for Adverse Events version 4.0). Analyses were on an intention-to-treat principle. Of 109 patients, 65% completed treatment. The cohort was 59% males, with 63% having high-intermediate risk IPI scores. At a median follow-up of 36.4 months, 15 relapses occurred (median, 8.2 months). The 2-year DFS was 87.9% (90% confidence interval [CI], 81.5-92.1), and the 2-year OS was 96.3% (90% CI, 91.7-98.3), meeting the primary objective. Treatment with salvage chemotherapy resulted in 10 of 13 patients achieving a second CMR. OS was significantly better among atezolizumab-treated patients than in a population-based matched control cohort from the Netherlands Cancer Registry. Adverse events (AEs) affected 79% of patients, with 18% developing immune-related AEs, including 4.5% grade 3 to 4. Atezolizumab consolidation significantly improved DFS in high-risk patients with DLBCL compared to historical cohorts. OS was significantly better than a population-based control cohort. These findings warrant further validation and assessment of immune checkpoint inhibitors as consolidation strategy in DLBCL. This trial was registered at www.clinicaltrials.gov as #NCT03463057.


  • Open Access

    Mucositis-associated bloodstream infections in adult haematology patients with fever during neutropenia: risk factors and the impact of mucositis severity

    by Nick A. de Jonge, Jeroen J. W. M. Janssen, Paula Ypma, Alexandra H. E. Herbers, Arne de Kreuk, Wies Vasmel, Jody M. W. van Den Ouweland, Aart Beeker, Otto Visser, Sonja Zweegman, et al.

    Purpose: Haematology patients with high-risk neutropenia are prone to mucosal-barrier injury-associated laboratory-confirmed bloodstream infections (MBI-LCBI). We assessed risk factors for MBI-LCBI including candidaemia in neutropenic haematology patients with fever. Methods: This prospective observational study was performed in six dedicated haematology units in the Netherlands. Eligible haematology patients had neutropenia < 500/mL for ≥ 7 days and had fever. MBI-LCBIs were classified according to Centers for Disease Control (CDC) definitions and were followed until the end of neutropenia > 500/mL or discharge. Results: We included 416 patients from December 2014 until August 2019. We observed 63 MBI-LCBIs. Neither clinical mucositis scores nor the blood level of citrulline at fever onset was associated with MBI-LCBI. In the multivariable analysis, MASCC-score (odds ratio [OR] 1.16, 95% confidence interval [CI] 1.05 to 1.29 per point decrease), intensive chemotherapy (OR 3·81, 95% CI 2.10 to 6.90) and Pichia kudriavzevii (formerly Candida krusei) colonisation (OR 5.40, 95% CI 1.75 to 16.7) were retained as risk factors for MBI-LCBI, while quinolone use seemed protective (OR 0.42, 95% CI 0.20 to 0.92). Citrulline level (OR 1.57, 95% CI 1.07 to 2.31 per µmol/L decrease), active chronic obstructive pulmonary disease (OR 15.4, 95% CI 1.61 to 14.7) and colonisation with fluconazole-resistant Candida (OR 8.54, 95% CI 1.51 to 48.4) were associated with candidaemia. Conclusion: In haematology patients with fever during neutropenia, hypocitrullinaemia at fever onset was associated with candidaemia, but not with bacterial MBI-LCBI. Patients with intensive chemotherapy with a low MASCC-score and colonisation with Pichia kudriavzevii had the highest risk of MBI-LCBI. Trial registration: ClinicalTrials.gov (NCT02149329) at 19-NOV-2014.


  • Open Access

    Prognostic value of histopathologic traits independent of stromal tumor-infiltrating lymphocyte levels in chemotherapy-naïve patients with triple-negative breast cancer

    by L.W. de Boo, K. Jóźwiak, N.D. Ter Hoeve, P.J. van Diest, M. Opdam, Y. Wang, M.K. Schmidt, V. de Jong, S. Kleiterp, S. Cornelissen, et al.


  • Open Access

    Combined Cabazitaxel and Carboplatin Treatment of Metastatic Castration Resistant Prostate Cancer Patients, With Innate or Acquired Resistance to Cabazitaxel Monotherapy

    by K. van der Zande, R.D. Tutuhatunewa-Louhanepessy, P. Hamberg, S. Ras, J.M. de Feijter, V.O. Dezentjé, A. Broeks, S. Cornelissen, A. Beeker, V. van der Noort, et al.


  • Open Access

    Survival, neurocognitive function, and health-related quality of life outcomes after rituximab—methotrexate, BCNU, teniposide, and prednisolone for primary CNS lymphoma: Final results of the HOVON 105/ALLG NHL 24 study

    by Jacoline E C Bromberg, Samar Issa, Bronno van der Holt, Matthijs van der Meulen, Linda Dirven, Monique C Minnema, Tatjana Seute, Marc Durian, Gavin Cull, Marjolein W M van der Poel, et al.

    Studies on the efficacy of rituximab in primary CNS lymphoma (PCNSL) reported conflicting results. Our international randomized phase 3 study showed that the addition of rituximab to high-dose methotrexate, BCNU, teniposide, and prednisolone (MBVP) in PCNSL was not efficacious in the short term. Here we present long-term results after a median follow-up of 82.3 months. One hundred and ninety-nine eligible newly diagnosed, nonimmunocompromised patients with PCNSL aged 18–70 years with WHO performance status 0–3 was randomized between treatment with MBVP chemotherapy with or without rituximab, followed by high-dose cytarabine consolidation in responding patients, and reduced-dose WBRT in patients aged ≤ 60 years. Event-free survival was the primary endpoint. Overall survival rate, neurocognitive functioning (NCF), and health-related quality of life (HRQoL) were additionally assessed, with the IPCG test battery, EORTC QLQ-C30 and QLQ-BN20 questionnaires, respectively. For event-free survival, the hazard ratio was 0.85, 95% CI 0.61–1.18, P = .33. Overall survival rate at 5 years for MBVP and R-MBVP was 49% (39–59) and 53% (43–63) respectively. In total, 64 patients died in the MBVP arm and 55 in the R-MBVP arm, of which 69% were due to PCNSL. At the group level, all domains of NCF and HRQoL improved to a clinically relevant extent after treatment initiation, and remained stable thereafter up to 60 months of follow-up, except for motor speed which deteriorated between 24 and 60 months. Although fatigue improved initially, high levels persisted in the long term. Long-term follow-up confirms the lack of added value of rituximab in addition to MBVP and HD-cytarabine for PCNSL.